Dublin, Aug. 18, 2017 (GLOBE NEWSWIRE) -- The "Antibody Discovery: Services and Platforms, 2017-2027" report has been added to Research and Markets' offering.

The Antibody Discovery: Services and Platforms, 2017-2027' report provides an extensive study on the current market landscape and future outlook of the antibody discovery service and platform providers. The study presents an in-depth analysis of a diverse set of companies that provide antibody discovery services and/or provide access to their platforms to drug developers.

The rising demand of personalized medicines to provide targeted treatment options has encouraged pharmaceutical companies to shift their focus from small molecules to discovery and development of biologics, particularly antibody based therapeutics. Antibodies, because of several advantages such as high specificity and targeted approach, are increasingly becoming crucial for the treatment of a number of diseases. In fact, since 2015, more than 20 antibodies have been approved by the USFDA. The growing popularity of antibody based therapeutics is also reflected from the dominance of these biologics in the portfolios of major biopharmaceutical companies.

At present, the focus of majority of biopharmaceutical companies is on discovering therapeutic antibodies against novel targets. However, discovery of antibodies is a long, arduous and costly process; as a result, there is a growing preference to outsource such operations. Drug developers are partnering with contract research organizations (CROs) that provide antibody discovery services using novel and advanced technologies.

Outsourcing enables biopharmaceutical companies/academic institutes accelerate their drug discovery process by leveraging the technical capabilities and expertise of CROs. Additionally, a number of drug developers and academic institutes have obtained rights to access novel antibody discovery platforms from technology providers. As the demand of novel therapeutic antibodies for various disease areas is expected to rise steadily, we are optimistic about the future of the contract research firms that are driving innovation in the drug discovery process.

The study features a detailed analysis of the existing size and potential future growth opportunities (2017-2027) in the antibody discovery services market. We have provided insights on the likely evolution of the market in different regions including North America, Europe, China and rest of the world. In addition, we have provided the likely evolution on the basis of the steps involved in antibody discovery (antigen designing, hit generation, lead selection, lead optimization and lead characterization), antibody discovery methods (phage display, hybridoma, transgenic animal based, yeast display, single cell based and others), and the nature of antibody generated (chimeric, humanized and fully human). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have presented three different forecast scenarios, depicting conservative, base and optimistic tracks of the market's evolution.

Key Topics Covered:

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION TO ANTIBODIES
3.1. Chapter Overview
3.2. Historical Background of Antibodies
3.3. Structure of Antibodies
3.4. Isotypes of Antibodies
3.5. Mechanism of Action of Antibodies
3.6. Polyclonal and Monoclonal Antibodies
3.7. Bispecific Antibodies
3.8. Applications of Antibodies

4. ANTIBODY DISCOVERY PROCESS AND METHODS
4.1. Chapter Overview
4.2. Antibody Discovery Process
4.3. Antibody Discovery Methods
4.4. Advantages and Disadvantages of Antibody Discovery Methods
4.5. Evolution of Monoclonal Antibodies: From Murine to Fully Human

5. COMPETITIVE LANDSCAPE
5.1. Chapter Overview
5.2. Antibody Discovery Services Providers: Overall Market Landscape
5.3. Antibody Discovery Platform Providers: Overall Market Landscape
5.3.1. Antibody Discovery Platform Providers: Analysis by Antibody Generation Methods
5.4. Antibody Discovery Platforms Used for In-house Purposes

6. ANTIBODY DISCOVERY SERVICES PROVIDERS
6.1. Overview
6.2. Antibody Discovery Services Providers: North America
6.2.1. Abwiz Bio
6.2.2. Aragen Bioscience (A GVK BIO Company)
6.2.3. LakePharma
6.3. Antibody Discovery Service Providers: Europe
6.3.1. Abzena
6.3.2. ModiQuest Research (Subsidiary of ModiQuest Group)
6.3.3. PX'Therapeutics (a Subsidiary of Aguettant Pharmaceutical Group)
6.4. Antibody Discovery Service Providers: Asia Pacific
6.4.1. ChemPartner
6.4.2. Viva Biotech
6.4.3. WuXi AppTec

7. ANTIBODY DISCOVERY PLATFORM PROVIDERS
7.1. Chapter Overview
7.2. Antibody Discovery Platform Providers: North America
7.2.1. Ligand Pharmaceuticals
7.2.2. TRIANNI
7.3. Antibody Discovery Platform Providers: Europe
7.3.1. AIMM Therapeutics
7.3.2. Kymab
7.4. Antibody Discovery Platform Providers: Asia Pacific
7.4.1. Harbour BioMed
7.5. Competitiveness Analysis: Antibody Discovery Platforms
7.5.1. Competitiveness Analysis: Library Based Antibody Discovery Platforms
7.5.2. Competitiveness Analysis: Transgenic Animal Based Antibody Discovery Platforms

8. OPPORTUNITY ANALYSIS
8.1. Chapter Overview
8.2. Forecast Methodology
8.3. Antibody Discovery Services Market, 2017-2027 (USD Billion)
8.4. Antibody Discovery Services Market, 2017-2027: Distribution by Regions (USD Billion)
8.5. Antibody Discovery Services Market, 2017-2027: Distribution by Steps Involved in Antibody Discovery Process (USD Billion)
8.6. Antibody Discovery Services Market, 2017-2027: Distribution by Antibody Discovery Methods (USD Billion)
8.7. Antibody Discovery Services Market, 2017-2027: Distribution by Nature of Antibody Generated (USD Billion)

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Antibody Discovery Services and Platforms: List of Partnerships

10. CASE IN POINT: DRUG DISCOVERY PROCESS OF TOP SELLING ANTIBODIES
10.1. Chapter Overview
10.2. Humira® (Adalimumab)
10.3. Remicade® (Infliximab)
10.4. Herceptin® (Trastuzumab)
10.5. Lucentis® (Ranibizumab)
10.6. Simponi® (Golimumab)

11. SURVEY ANALYSIS
11.1. Chapter Overview
11.2. Seniority Level of Respondents
11.3. Steps of Antibody Discovery for which Services are Provided
11.4. Antibody Discovery Methods
11.5. Type of Antibody Discovered
11.6. Location of Antibody Discovery Facility / Laboratory
11.7. Likely Market Size

12. CONCLUSION
12.1. High Costs, Process Complexity and Lack of Internal Resources have Led to Increased Outsourcing in Antibody Discovery
12.2. A Number of Platform Providers, With an Aim to Support Antibody Discovery Operations of Drug Developers / CROs, have Emerged
12.3. Flexible Partnership Models have Fostered Collaborations between Drug Developers and CROs / Technology Providers
12.4. In Order to Maintain a Competitive Edge in the Growing Antibody Discovery Field, the Companies are Developing Innovative Technologies
12.5. Driven by the Rising Demand for Targeted Therapies, the Market is Likely to Witness Continuous Growth in the Coming Decade

13. INTERVIEW TRANSCRIPTS
13.1. Chapter Overview
13.2. Aaron Sato, Chief Scientific Officer, LakePharma
13.3. Debra Valsamis, Business Development Associate, Antibody Solutions
13.4. Christel Iffland, Vice President, Ligand Pharmaceuticals
13.5. Ignacio Pino, President and CEO, CDI Laboratories
13.6. Jeng Her, CEO, AP Biosciences
13.7. Thomas Schirrmann, CEO and General Manager, YUMAB

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/research/lb9sxz/antibody

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Biopharmaceuticals